Reports + MCP · for Medical Affairs and scientific communications
A sourced briefing on how a congress presentation was received.
Congress commentary moves fast and scatters across podcasts, posts and video. A briefing needs the source behind each view.
When you need it
- ASCO, ESMO, ASH, SABCS and other major congresses
- A late-breaking abstract in your therapeutic area
- A competitor's oral presentation
Ask your agent
“Brief me on the HCP reaction to the late-breaking abstracts in our therapeutic area at this congress, with sources.”
More to ask
- “Which reports changed since the congress opened, and what changed in each?”
- “What did clinicians say about our competitor's presentation on day one, and did anything shift by day three?”
- “List the podcast episodes recorded after the congress that discuss PROUD-PV, with timestamps.”
- “Who were the speakers in those episodes? Give each one's specialty, practice and research affiliations, and say which identities are verified.”
Before and after
How the work changes
Today
- Ask colleagues who attended for their impressions
- Track a congress hashtag that mixes HCPs, patients and companies
- Assemble a recap after the moment to act has passed
With Erudio
- Posts, podcasts and video in one search, filtered by date
- Report changes since the edition you already read
- Every reaction linked to its source, so the brief survives scrutiny
What you get
- Early reactions to presentations, attributed and linked
- Questions raised from the floor and online
- Later clarifications that changed the first reading
Tools it calls
mcp
search({ "query": "<trial> <congress>", "published_after": "<date>" })
fetch_x_thread_sources({ "conversation_id": "<id>" })
lookup_profile({ "names": ["<speaker>", "<speaker>"] })
search_reports({ "updated_since": "<datetime>" })
get_report_changes({ "report_id": "<id>", "since_edition": <n> })In a published report
PROUD-PV
NCT01949805
The long-term PROUD-PV reading: what clinicians took from molecular response, earlier treatment and the time-dependent result.
- F1Molecular response is gaining clinical meaning, but its role in changing treatment remains contested
- F2Earlier cytoreduction in low-risk PV attracts support, but deferral remains an active-management position
- F3The favorable reading is time-dependent and must remain beside the early endpoint and extension qualifications
What it does not do
- Coverage depends on what is public and retrievable. Every report states its known gaps.
- Early reactions are labeled with their date, so later clarifications are not hidden.
- No ranking of presenters or sessions.